In 2016, a landmark report was issued on the global problem of antimicrobial resistance. The paper, commissioned by the U.K. government and the Wellcome Trust, sought to quickly grab the attention of policymakers — by tapping a former high-profile Goldman Sachs economist named Jim O’Neill to lead the effort. He issued a particularly dire warning of what was to come if the issue was ignored.
“It is fair to assume that over 1 million people will have died from antimicrobial resistance since I started this review in the summer of 2014. This is truly shocking,” O’Neill wrote at the time, adding that the cost in terms of lost global production between now and 2050 would be an enormous $100 trillion if action was not taken.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
